Results 221 to 230 of about 46,843 (269)

Allochthonous zoonotic sporotrichosis in the Brazilian Central-West: diagnostic challenges in a nonendemic area. [PDF]

Rev Inst Med Trop Sao Paulo
Vieira TB, Thies SF, Dias LC, Oliveira BM, Silveira F, Vieira JMC, Barreto ES, Rodrigues ACB, Coppola MM, Marcolongo-Pereira C, Faria RO, Gomes ADR.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

A randomised trial of prednisolone versus prednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma

European Respiratory Journal, 2021
Background Whether a combination of glucocorticoid and antifungal triazole is superior to glucocorticoid alone in reducing exacerbations in patients with allergic bronchopulmonary aspergillosis (ABPA) remains unknown. We aimed to compare the efficacy and
R. Agarwal, V. Muthu, I. Sehgal, S. Dhooria, K. Prasad, M. Garg, A. Aggarwal, A. Chakrabarti   +7 more
semanticscholar   +1 more source

Hepatic Safety of Itraconazole [PDF]

Journal of Cutaneous Medicine and Surgery, 2002
Background: As the use of the newer oral antifungal agents for the treatment of superficial fungal infections becomes more widespread, the issue of safety surrounding their use is becoming an increasingly important consideration. Itraconazole is effective and well tolerated, with most side effects being minor and reversible.
James Q. Del Rosso, Elisabeth Chwetzoff, Aditya K. Gupta, Robert Baran   +3 more
openaire   +2 more sources

Itraconazole attenuates the stemness of nasopharyngeal carcinoma cells via triggering ferroptosis

Environmental Toxicology, 2020
Radiotherapy is a common therapy method for nasopharyngeal carcinoma (NPC) treatment; however, radioresistance greatly limits the clinical efficiency and prognosis of NPC patients.
Ying Xu, Qian Wang, Xiaozhen Li, Yingyan Chen, Gang Xu   +4 more
semanticscholar   +1 more source

Itraconazole

Expert Opinion on Pharmacotherapy, 2000
Itraconazole is a broad spectrum triazole antifungal agent. It has favourable pharmacodynamic and pharmacokinetic profiles and is available as both oral and i.v. formulations. Over the last two decades, clinical and animal infection studies have demonstrated the efficacy of itraconazole in a wide range of superficial fungal infections including ...
G E, Piérard, J E, Arrese, C, Piérard-Franchimont   +2 more
openaire   +2 more sources

Pharmacology of Itraconazole

Drugs, 2001
Itraconazole is a triazole antifungal agent that has a broad spectrum of activity and is well tolerated. Itraconazole is highly efficacious, particularly because its main metabolite, hydroxy-itraconazole, also has considerable antifungal activity. The original capsule formulation of itraconazole may lead to variability in absorption and the plasma ...
Karel De Beule, Jef van Gestel
openaire   +3 more sources

Intravenous Itraconazole

Annals of Pharmacotherapy, 2001
OBJECTIVE: To review the pharmacology, mycology, chemistry, pharmacokinetics, efficacy, safety, tolerability, dosage, administration, and economic issues of intravenous itraconazole. DATA SOURCES: A MEDLINE search from 1978 to June 2000 of the English-language literature and an extensive review of meeting abstracts was conducted.
D, Slain, P D, Rogers, J D, Cleary, S W, Chapman   +3 more
openaire   +2 more sources

Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole

Clinica Chimica Acta, 2013
The pharmacokinetic variability of hydroxy-itraconazole (OH-ITZ), an active metabolite of itraconazole (ITZ), is not fully known.Oral solution of ITZ was administered in 46 immunocompromised patients as a single 200 mg dose for at least 12 days. The plasma concentrations of ITZ, active OH-ITZ, and keto-itraconazole (keto-ITZ), an inactive metabolite ...
Takahiro Yamada, Junichi Kawakami, Yasuaki Mino, Tatsuya Yagi, Takayuki Watanabe, Takayuki Watanabe, Hiroshi Yamada, Takafumi Naito   +7 more
openaire   +3 more sources

Treatment of paracoccidioidomycosis with itraconazole

Medical Mycology, 1990
Forty-seven patients with active paracoccidioidomycosis were treated with itraconazole. The majority of the patients (45) had the chronic adult form of the disease while the remaining exhibited the juvenile form. All of the patients received itraconazole, 100 mg day-1, with the exception of two for whom the clinical condition necessitated a larger dose.
M. I. Múnera, P. Restrepo, Iván Gómez, M. S. Naranjo, M. Trujillo, Angela Restrepo   +5 more
openaire   +2 more sources

Treatment of Aspergillosis with Itraconazole

Annals of Pharmacotherapy, 1993
OBJECTIVE: To review the role of itraconazole as oral therapy for the major infections caused by Aspergillus spp.: allergic bronchopulmonary aspergillosis, aspergilloma, and invasive aspergillosis. DATA SOURCES: A MEDLINE search of articles published in the English language between 1986 and 1993 was used to identify relevant citations, including review
Timothy S. Jennings, Thomas C. Hardin
openaire   +3 more sources